MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Hikma Pharmaceuticals Plc Company Profile (LON:HIK)

Consensus Ratings for Hikma Pharmaceuticals Plc (LON:HIK) (?)
Ratings Breakdown: 10 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 2,486.75

Analysts' Ratings History for Hikma Pharmaceuticals Plc (LON:HIK)
Show:
DateFirmActionRatingPrice TargetActions
6/24/2016Stifel NicolausReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016JPMorgan Chase & Co.Reiterated RatingOverweightGBX 2,300View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016BarclaysBoost Price TargetOverweightGBX 2,760 -> GBX 2,800View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016Jefferies GroupReiterated RatingBuyGBX 2,355View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016HSBCReiterated RatingBuyGBX 2,525View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Panmure GordonUpgradeBuyGBX 2,120View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016AlphaValueReiterated RatingBuyGBX 2,554View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015Goldman SachsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2015Shore CapitalUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015Beaufort SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Hikma Pharmaceuticals Plc (LON:HIK)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Hikma Pharmaceuticals Plc (LON:HIK)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Hikma Pharmaceuticals Plc (LON:HIK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
3/11/2015GBX 0.210.64%4/16/20154/16/20155/21/2015Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Hikma Pharmaceuticals Plc (LON:HIK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016Darwazah,MazenInsiderBuy150,000GBX 2,200£3,300,000Tweet This Trade  Share This Trade on StockTwits
6/17/2016Al-Husry,AliInsiderBuy70,000GBX 22£15,400Tweet This Trade  Share This Trade on StockTwits
5/9/2016Darwazah,SaidInsiderBuy17,440GBX 2,228£388,563.20Tweet This Trade  Share This Trade on StockTwits
4/26/2016Darwazah,SaidInsiderBuy10,000GBX 2,260£226,000Tweet This Trade  Share This Trade on StockTwits
4/25/2016Darwazah,SaidInsiderBuy10,000GBX 2,324£232,400Tweet This Trade  Share This Trade on StockTwits
4/22/2016Darwazah,SaidInsiderBuy30,000GBX 2,325£697,500Tweet This Trade  Share This Trade on StockTwits
4/20/2016Darwazah,SaidInsiderBuy30,000GBX 2,271£681,300Tweet This Trade  Share This Trade on StockTwits
4/19/2016Darwazah,SaidInsiderBuy30,000GBX 2,266£679,800Tweet This Trade  Share This Trade on StockTwits
4/11/2016J. Castellani,JohnInsiderBuy2,500GBX 2,103£52,575Tweet This Trade  Share This Trade on StockTwits
4/7/2016Darwazah,MazenInsiderBuy60,000GBX 2,118£1,270,800Tweet This Trade  Share This Trade on StockTwits
4/5/2016Darwazah,SaidInsiderBuy30,000GBX 2,055£616,500Tweet This Trade  Share This Trade on StockTwits
3/31/2016Darwazah,SaidInsiderBuy30,000GBX 1,972£591,600Tweet This Trade  Share This Trade on StockTwits
3/24/2016Butler,PatInsiderBuy2,500GBX 1,920£48,000Tweet This Trade  Share This Trade on StockTwits
3/21/2016Pickering ,RobertInsiderBuy2,500GBX 1,856£46,400Tweet This Trade  Share This Trade on StockTwits
8/27/2015Kirby,PamelaInsiderBuy3,317GBX 2,264£75,096.88Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Hikma Pharmaceuticals Plc (LON:HIK)
DateHeadline
06/29/16 03:28 AMEuropean healthcare first sector to recover Brexit losses - [Reuters] - The rush to large-cap, high quality, dividend-paying pharmaceutical stocks in the aftermath of Brexit has helped Europe's healthcare index erase all its losses since last week's vote. The healthcare index, up 1.4 percent on Wednesday, is the only regional sector index to trade above last Thursday's close.
06/27/16 08:49 AMHikma Pharmaceuticals : acquires six injectable products in Europe
06/27/16 03:46 AMHikma Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : HIK-GB : June 27, 2016 -
06/26/16 03:53 PMEarnings are set to sink at Burberry Group plc, Hikma Pharmaceuticals plc and J Sainsbury plc! Should you buy? - Motley Fool UK
06/24/16 10:54 AMHikma Pharmaceuticals PLC (LON:HIK) stock price target held steady to GBX0 as recorded today by Stifel
06/24/16 03:10 AMHikma acquires six injectable products in Europe - [at noodls] - London, 24 June 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces ...
06/23/16 07:21 AMRoyal Jordanian : Said Darwazeh elected RJ Chairman of the Board of Directors; Suleiman Obeidat appointed a board member
06/23/16 07:21 AMSaid Darwazeh elected RJ chairman of the board of directors
06/22/16 04:33 PMRJ elects Darwazeh as chairman of Board of Directors
06/20/16 04:13 PMShould you buy or sell Majestic Wines plc, Enquest plc and Hikma Pharmaceuticals plc after today's news? - Yahoo Finance UK
06/20/16 02:34 PMHikma Pharmaceuticals Plc – Value Analysis (LONDON:HIK) : June 20, 2016 -
06/18/16 08:51 AMNewly released market study: Schistosomiasis Global Clinical Trials Review, H1, 2016
06/15/16 04:29 PMUK stocks higher at close of trade; Investing.com United Kingdom 100 up 0.78% - Investing.com
06/14/16 03:50 AMHikma Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : HIK-GB : June 14, 2016 -
06/13/16 11:49 AMHikma receives FDA approval for Letrozole Tablets - [at noodls] - London, 13 June 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces ...
06/09/16 04:34 PMHikma seeks dismissal of Takeda's bid to block gout drug sales
06/07/16 03:38 AMHikma Pharmaceuticals Egypt launches Hikma Specialized division to bring advanced affordable medicines to patients in need - [at noodls] - Cairo, June, 2016 - Hikma Pharmaceuticals Egypt announced early this month, the launch of its new business unit 'Hikma Specialized Egypt' as part of their strategic vision focusing on high need areas and ...
06/06/16 04:20 PMHikma Pharmaceuticals : receives FDA approval for Ketamine Hydrochloride Injection
06/04/16 04:28 PMHikma Pharmaceuticals Plc (HIK) Stock Rating Reaffirmed by JPMorgan Chase & Co. - Let Me Know About This
06/03/16 07:04 AMJP Morgan Cazenove Gives Hikma Pharmaceuticals PLC Price Target With Potential 0.09% Upside - FTSE News - FTSE NewsJP Morgan Cazenove Gives Hikma Pharmaceuticals PLC Price Target With Potential 0.09% UpsideFTSE NewsJP Morgan Cazenove gave the share price of Hikma Pharmaceuticals PLC a price target of 2300 meaning the broker expects a potential upside of 0.09% from Hikma Pharmaceuticals PLC's current market price of 2298. Hikma Pharmaceuticals PLC has ...Hikma Pharmaceuticals (LON:HIK) Analyst Target ChangesShare Trading Newsall 3 news articles »
06/03/16 06:53 AMIn fight for GSK's Advair, generic firms step carefully on price - [Reuters] - Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price. "Nobody wants to kill the market," said Rajiv Malik, president of Mylan, which will have the first commercial Advair copy, assuming U.S. regulators approve its substitutable generic device by a target date of March 28, 2017.
06/02/16 07:10 AMHikma Pharmaceuticals hits Footsie as oil and mining dip - Proactive Investors UK - Proactive Investors UKHikma Pharmaceuticals hits Footsie as oil and mining dipProactive Investors UKDrug company Hikma Pharmaceuticals PLC (LON:HIK) ascended to the FTSE 100 Index as the decline of oil and mining in London's top flight continued. Hikma is set to enter the FTSE 100 in the latest quarterly review of the index at the expense of ...JP Morgan Cazenove Gives Hikma Pharmaceuticals PLC Price Target With Potential 0.09% UpsideFTSE NewsHikma Pharmaceuticals bounces back into FTSE 100EveryInvestorFTSE 100 ETFs in focus as UK index completes quarterly reviewETF Strategyall 4 news articles »
06/01/16 04:45 PMJP Morgan Releases Hikma Pharmaceuticals PLC Price Target With Potential 0.57% Upside - Share Trading News - Share Trading NewsJP Morgan Releases Hikma Pharmaceuticals PLC Price Target With Potential 0.57% UpsideShare Trading NewsJP Morgan gave shares of Hikma Pharmaceuticals PLC a price target of 2300 indicating a possible upside of 0.57% from Hikma Pharmaceuticals PLC's existing share price of 2287. Hikma Pharmaceuticals PLC currently has 199,380,000 shares which are ...Hikma Pharmaceuticals PLC (LON:HIK) Investors: JP Morgan Cazenove Keeps “Overweight” Rating, Sees GBX ...The PostHikma Pharmaceuticals PLC (LON:HIK) Receives Overweight Rating From JP Morgan Cazenove AnalystsRisers & FallersA Reversal for Hikma Pharmaceuticals Plc Is Not Near. The Stock Rises AgainHNNall 5 news articles »
05/27/16 09:56 AMHikma Pharmaceuticals plc set for FTSE 100 re-entry and Inmarsat plc for ejection -
05/24/16 10:56 AMMichael Raya, CEO of West-Ward Pharmaceuticals, Hikma’s wholly-owned subsidiary in the US, joins GPhA Board - [at noodls] - Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, joins GPhA Board London, 24 May 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: ...
05/24/16 05:26 AMFurther re Colchicine Litigation - [at noodls] - Hikma wins Mitigare / Colchicine patent infringement case London, 19 May 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), ...
05/24/16 05:26 AMDoc re. Bond Guarantor Group - [at noodls] - 6 May 2016 NOTICE OF ACCESSION OF GUARANTORS Hikma Pharmaceuticals Public Limited Company (the 'Issuer') Notice to the holders of the outstanding U.S.$500,000,000 4.25 per cent. Guaranteed Notes due 2020 ...
05/20/16 03:19 PMHikma Pharmaceuticals Plc : Neutral outlook but great fundamentals -
05/19/16 09:10 AMUS court dismisses Takeda's claims against Hikma Pharmaceuticals -
05/14/16 08:53 AMHikma Pharmaceuticals Plc 26% Potential Upside Indicated by Barclays Capital - DirectorsTalk Interviews - Risers & FallersHikma Pharmaceuticals Plc 26% Potential Upside Indicated by Barclays CapitalDirectorsTalk InterviewsHikma Pharmaceuticals Plc using EPIC/TICKER code LON:HIK has had its stock rating noted as 'Reiterates' with the recommendation being set at 'OVERWEIGHT' today by analysts at Barclays Capital. Hikma Pharmaceuticals Plc are listed in the Health Care ...UK stocks higher at close of trade; Investing.com United Kingdom 100 up 0.64%Investing.comall 489 news articles »
05/12/16 09:42 AMBRIEF-Hikma Pharma reiterates guidance for 2016 - May 12 Hikma Pharmaceuticals Plc : * Hikma reiterates guidance for 2016 * Continue to expect full year group revenue to be in range of $2.0 billion to $2.1 billion * Remain on track to deliver global injectables revenue growth in mid to high-single digits ...
05/11/16 07:18 PMHikma paints positive picture as investors gather -
05/09/16 08:53 AMIs AstraZeneca plc set to lose out to Hikma Pharmaceuticals plc and BTG plc? - Motley Fool UK - Is AstraZeneca plc set to lose out to Hikma Pharmaceuticals plc and BTG plc?Motley Fool UKIn the last three months, shares in AstraZeneca (LSE: AZN) have performed relatively poorly. They're down by almost 8% and with sector peers such as Hikma (LSE: HIK) and BTG (LSE: BTG) rising by 5% and 2%, respectively, during the same time period, ...and more »
05/09/16 03:36 AMHikma receives Drug Shortage Assistance Award from US FDA - [at noodls] - London, 09 May 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, is ...
05/06/16 09:10 AMEXTRA: Smurfit Kappa Profit Rises Ahead Of Upcoming FTSE Inclusion - At present, that would not be enough to make Smurfit large enough for automatic FTSE 100 inclusion but would make it the second-largest company in the FTSE 250 behind recent FTSE 100 drop-out Hikma Pharmaceuticals PLC. Should Smurfit be included in the ...
05/06/16 09:10 AMFTC Approves $2.2B Hikma Deal, Pending Divestitures - Law360, New York (May 5, 2016, 6:24 PM ET) -- The U.S. Federal Trade Commission signed off on Hikma Pharmaceuticals PLC’s $2.2 billion purchase of Boehringer’s U.S. generics business Thursday, after the U.K. drugmaker agreed to divest certain assets to ...
05/06/16 09:10 AMHikma Pharmaceuticals : receives FDA approval for Fluphenazine Decanoate Injection - Release date- 04052016 - London- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its supplemental Abbreviated New ...
05/04/16 04:10 AMHikma receives FDA approval for Fluphenazine Decanoate Injection - [at noodls] - London, 04 May 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces ...
05/04/16 04:10 AMHikma receives FDA approval for Leucovorin Calcium Injection - [at noodls] - London, 04 May 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces ...
04/29/16 09:48 AMHow Many Hikma Pharmaceuticals Plc (LON:HIK)'s Analysts Are Bullish? - B.O.D.Y Confidential - How Many Hikma Pharmaceuticals Plc (LON:HIK)'s Analysts Are Bullish?B.O.D.Y ConfidentialOut of 11 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 11 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Hikma Pharmaceuticals PLC has been the topic of 63 analyst reports since July 29, 2015 according to ...
04/26/16 01:04 PMETF’s with exposure to Hikma Pharmaceuticals Plc : April 26, 2016 -
04/20/16 12:58 PMDirector dealings: Hikma gets shot in the arm as chief tops up -
04/20/16 10:47 AMAnalysts Consensus For Hikma Pharmaceuticals (LON:HIK) - Risers & Fallers - Analysts Consensus For Hikma Pharmaceuticals (LON:HIK)Risers & FallersHikma Pharmaceuticals PLC is a pharmaceutical company engaged the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company is ...and more »
04/19/16 10:49 AMBoehringer's operating profit up 6 percent on diabetes drugs - Excluding Boehringer's U.S. generics business - sold to Hikma Pharmaceuticals Plc at the beginning of this year - and the effect of currency swings, sales rose 5.3 percent. Full-year operating profit rose to 2.3 billion euros ($2.60 billion), on 14.8 ...
04/15/16 01:24 PMHikma Pharmaceuticals Plc's (HIK) Buy Rating Reiterated at Jefferies Group - Washington News Wire - Hikma Pharmaceuticals Plc's (HIK) Buy Rating Reiterated at Jefferies GroupWashington News WireHikma Pharmaceuticals Plc logo Jefferies Group reissued their buy rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a report released on Monday, MarketBeat.com reports. The firm currently has a GBX 2,355 ($33.62) price objective on the stock.J. Castellani,John Acquires 2500 Shares of Hikma Pharmaceuticals Plc (HIK) StockWeb Breaking Newsall 4 news articles »
04/12/16 01:14 PMHikma Pharmaceuticals PLC (LON:HIK) Investors: Citigroup Reiterates Buy Rating - Stock Caller - Stock CallerHikma Pharmaceuticals PLC (LON:HIK) Investors: Citigroup Reiterates Buy RatingStock CallerCitigroup reconfirmed their Buy rating on Hikma Pharmaceuticals PLC (LON:HIK)'s stock in a research report sent to investors on 11 April. Out of 11 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 10 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This ...Hikma Pharmaceuticals Plc (LON:HIK) Receives GBX 2434.14 Consensus PT from AnalystsWeb Breaking NewsHikma Pharmaceuticals Plc's (HIK) Buy Rating Reiterated at Citigroup Inc.Mas Market NewsHikma Pharmaceuticals (LON:HIK) Broker RoundupShare Trading Newsall 8 news articles »
04/12/16 11:22 AMDirector dealing: Hikma directors keep buying -
04/08/16 03:56 PMETF’s with exposure to Hikma Pharmaceuticals Plc : April 8, 2016 -
04/08/16 01:04 AMHikma’s ANDA for Generic Advair Diskus® accepted for filing by FDA - [at noodls] - London, 8 April 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today ...
03/28/16 07:41 PMHikma subsidiary receives FDA approval for Temozolomide capsules -
About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc logoHikma Pharmaceuticals PLC is a pharmaceutical company engaged the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company is focused on therapeutic areas, such as oncology, diabetes and cardiovascular and central nervous system (CNS). The Company's operations are conducted through three business segments: Branded, Injectables and Generics. Its Branded business manufactures and markets generic and in-licensed originator products across the Middle East and North Africa (MENA) region. Its Injectables business manufactures and markets branded and non-branded generic injectable products in the United States, Europe and MENA. Its Generics business manufactures non-branded oral generic products for sale in the United States market. It operates primarily in the MENA region, the United States and Europe.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: HIK
  • CUSIP:
Key Metrics:
  • Previous Close: $31.47
  • 50 Day Moving Average: $2253.11
  • 200 Day Moving Average: $2098.85
  • P/E Ratio: 19.29
  • P/E Growth: 1.26
  • Market Cap: $4.82B
  • Current Quarter EPS Consensus Estimate: $1.16 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha